Log in

NASDAQ:CTMX - CytomX Therapeutics Stock Price, Forecast & News

$7.13
+0.10 (+1.42 %)
(As of 02/17/2020 04:40 AM ET)
Add
Today's Range
$6.92
Now: $7.13
$7.26
50-Day Range
$6.75
MA: $7.65
$8.59
52-Week Range
$5.10
Now: $7.13
$19.20
Volume258,374 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:CTMX
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees137
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.


CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics Inc (NASDAQ:CTMX) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.13. The biotechnology company earned $10.71 million during the quarter, compared to analyst estimates of $23.58 million. View CytomX Therapeutics' Earnings History.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for CytomX Therapeutics.

What price target have analysts set for CTMX?

9 brokerages have issued 12 month price targets for CytomX Therapeutics' shares. Their forecasts range from $8.00 to $23.00. On average, they expect CytomX Therapeutics' stock price to reach $16.63 in the next year. This suggests a possible upside of 133.2% from the stock's current price. View Analyst Price Targets for CytomX Therapeutics.

What is the consensus analysts' recommendation for CytomX Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytomX Therapeutics.

What are Wall Street analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:
  • 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (8/15/2019)
  • 2. Nomura analysts commented, "Progressing IO Probody CX-072—next steps 2H19: CX-072 (PD-L1) in combo with full dose ipi (3mg/kg) is well tolerated—plans for next phase of combo will be revealed in near future. We view undifferentiated pleomorphic sarcoma as offering potentially easier CX-072 combo differentiation vs ipi/PD- (L)1, where this combo has not been tolerated. Monotherapy next steps in 2H19, but based on single-arm expansion data, we still see oppy for monotherapy strategy (e.g., autoimmune disease pts/pts intolerant to PD-1). Solid tumor candidate Ph2 dose, indication: Ph2 registration-worthy? Recall, CTMX saw responses to CX- 2009 in solid-tumor pts including those who failed TROP2 from IMMU. CX- 2009 still in dose refinement, starting at 8mg/kg and using a modified toxicity probability interval (mTPI) design." (8/11/2019)
  • 3. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Overweight rating and 12-month price target of $21/share. CytomX stock currently trades at an EV of ~$100M ($8.80/sh cash), and the shares are down about 27% YTD (vs. +8.5% for NBI), triggered by updates at its R&D day earlier this year. We believe that the company’s lead early-stage clinical assets, based on modified antibodies, are partially de-risked and are highly discounted at the current valuation. For CX-2009, we think that evolving clinical updates in the next 6-12 months should alleviate investor concerns about its safety profile and that risk of potential clinical setback is overstated." (5/13/2019)
  • 4. HC Wainwright analysts commented, "We utilize a probability of approval of 70% for we employ a 10% discount rate, and a 29% effective tax rate, yielding a total value of $1.6B, or a price per share of $34, assuming 47.6M shares outstanding and roughly $329M in cash and equivalents as of end-4Q19." (4/3/2019)

Has CytomX Therapeutics been receiving favorable news coverage?

Headlines about CTMX stock have trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. CytomX Therapeutics earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for CytomX Therapeutics.

Are investors shorting CytomX Therapeutics?

CytomX Therapeutics saw a drop in short interest in January. As of January 15th, there was short interest totalling 1,560,000 shares, a drop of 32.8% from the December 31st total of 2,320,000 shares. Based on an average trading volume of 483,200 shares, the days-to-cover ratio is presently 3.2 days. Approximately 3.5% of the company's stock are short sold. View CytomX Therapeutics' Current Options Chain.

What other stocks do shareholders of CytomX Therapeutics own?

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the folowing people:
  • Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)
  • Mr. Debanjan Ray, Sr. VP & CFO (Age 41)
  • Dr. Rachel Wallach Humphrey, Sr. VP & Chief Medical Officer (Age 58)
  • Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)
  • Dr. W. Michael Kavanaugh, Sr. VP, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63)

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (6.25%), Victory Capital Management Inc. (6.19%), Renaissance Technologies LLC (4.54%), State Street Corp (2.18%), FMR LLC (1.82%) and BVF Inc. IL (1.69%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Lloyd A Rowland, Rachel Humphrey and Sean A Mccarthy. View Institutional Ownership Trends for CytomX Therapeutics.

Which major investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, State Street Corp, Spark Investment Management LLC, Congress Park Capital LLC, FMR LLC, Bank of America Corp DE, UBS Group AG and Citigroup Inc.. View Insider Buying and Selling for CytomX Therapeutics.

Which major investors are buying CytomX Therapeutics stock?

CTMX stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Panagora Asset Management Inc., Marshall Wace LLP, Victory Capital Management Inc., Victory Capital Management Inc., Assenagon Asset Management S.A. and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for CytomX Therapeutics.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $7.13.


MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  314 (Vote Outperform)
Underperform Votes:  244 (Vote Underperform)
Total Votes:  558
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel